BRAF and colorectal carcinoma: Researchers have observed higher levels of PI3K/AKT pathway activation in CRC than those in other cancer types (even in BRAF mutated specimens) (Ebi et al., 2011), indicating a critical role of PI3K/AKT pathway in cancer.